Marinus Pharma (MRNS) Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
Get Alerts MRNS Hot Sheet
Join SI Premium – FREE
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.
“Upon completion, the sale of the PRV will significantly strengthen Marinus’ financial position, which we believe extends our cash runway into the fourth quarter of 2023,” said Steven Pfanstiel, Chief Financial Officer of Marinus. “Importantly, this non-dilutive funding will allow us to maintain momentum advancing our clinical pipeline, including the two ongoing Phase 3 trials in status epilepticus and tuberous sclerosis complex, and focus on the commercial launch of ZTALMY.”
Marinus received the voucher in March 2022 under a U.S. Food and Drug Administration program intended to encourage the development of treatments for rare pediatric diseases. Marinus was awarded the voucher when it received approval of ZTALMY® (ganaxolone) oral suspension CV for the treatment of seizures associated with CDKL5 deficiency disorder, a rare form of genetic epilepsy, in patients two years of age and older.
Marinus will receive a lump sum payment of $110 million upon the closing of the transaction, which is subject to customary closing conditions and is expected to occur following the expiration of the applicable U.S. antitrust clearance requirements.
Jefferies LLC acted as the exclusive financial advisor to Marinus for this transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002
- Genco Shipping & Trading Limited (GNK) Sends Letter to Shareholders
- Renovaro Biosciences (RENB) to Acquire Cyclomics
Create E-mail Alert Related Categories
Corporate News, FDA, Management Comments, Mergers and AcquisitionsRelated Entities
Jefferies & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!